Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.

Ruben Iglesias GomezRaúl MéndezTomás Palanques-Pastor Octavio Ballesta-LópezConxa Borrás AlmenarJuan Eduardo Megías-VericatEduardo López-BrizIsabel Font-NogueraRosario Menéndez VillanuevaJosé Andrés Román IborraJosé Luis Poveda Andrés

Published in: European journal of hospital pharmacy : science and practice (2021)

Patients treated with baricitinib for severe COVID-19 showed improvements in clinical and analytical values without relevant adverse events and 100% overall survival. Clinical randomised trials are needed to confirm the clinical benefit of baricitinib.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
clinical trial
early onset
ejection fraction
chronic kidney disease
randomized controlled trial
study protocol
patient reported outcomes
placebo controlled